K
Kieran F. Docherty
Researcher at University of Glasgow
Publications - 114
Citations - 7287
Kieran F. Docherty is an academic researcher from University of Glasgow. The author has contributed to research in topics: Heart failure & Ejection fraction. The author has an hindex of 18, co-authored 68 publications receiving 3298 citations. Previous affiliations of Kieran F. Docherty include Golden Jubilee National Hospital & Western Infirmary.
Papers
More filters
Journal ArticleDOI
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
John J.V. McMurray,Scott D. Solomon,Silvio E. Inzucchi,Lars Køber,Mikhail Kosiborod,Felipe Martinez,Piotr Ponikowski,Marc S. Sabatine,Marc S. Sabatine,Inder S. Anand,Jan Bělohlávek,Michael Böhm,Chern-En Chiang,Chern-En Chiang,Vijay K. Chopra,Rudolf A. de Boer,Akshay S. Desai,Mirta Diez,Jarosław Drożdż,Andrej Dukát,Junbo Ge,Jonathan G. Howlett,Jonathan G. Howlett,Tzvetana Katova,Masafumi Kitakaze,Charlotta Ljungman,Béla Merkely,Jose C. Nicolau,Eileen O'Meara,Mark C. Petrie,Pham Nguyen Vinh,Morten Schou,Tereshchenko Sn,Subodh Verma,Claes Held,David L. DeMets,Kieran F. Docherty,Pardeep S. Jhund,Olof Bengtsson,Mikaela Sjöstrand,AM Langkilde +40 more
TL;DR: Among patients with heart failure and a reduced ejection fraction, the risk of worsening heart failure or death from cardiovascular causes was lower among those who received dapagliflozin than amongThose who received placebo, regardless of the presence or absence of diabetes.
Journal ArticleDOI
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
Søren Lund Kristensen,Søren Lund Kristensen,Rasmus Rørth,Rasmus Rørth,Pardeep S. Jhund,Kieran F. Docherty,Naveed Sattar,David Preiss,Lars Køber,Mark C. Petrie,John J.V. McMurray +10 more
TL;DR: Overall, GLP-1 receptor agonist treatment reduced MACE by 12% and there was no increase in risk of severe hypoglycaemia, pancreatitis, or pancreatic cancer.
Journal ArticleDOI
Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes
Mark C. Petrie,Subodh Verma,Kieran F. Docherty,Silvio E. Inzucchi,Inder S. Anand,Jan Belohlavek,Michael Böhm,Chern-En Chiang,Chern-En Chiang,Vijay K. Chopra,Rudolf A. de Boer,Akshay S. Desai,Mirta Diez,Jarosław Drożdż,Andre Dukát,Junbo Ge,Jonathan G. Howlett,Tzvetana Katova,Masafumi Kitakaze,Charlotta Ljungman,Béla Merkely,Jose C. Nicolau,Eileen O'Meara,Pham Nguyen Vinh,Morten Schou,Tereshchenko Sn,Lars Køber,Mikhail Kosiborod,Anna Maria Langkilde,Felipe Martinez,Piotr Ponikowski,Marc S. Sabatine,Mikaela Sjöstrand,Scott D. Solomon,Per Johanson,Peter J. Greasley,David W. Boulton,Olof Bengtsson,Pardeep S. Jhund,John J.V. McMurray +39 more
TL;DR: In this exploratory analysis of a randomized trial of patients with HFrEF, dapagliflozin compared with placebo, when added to recommended therapy, significantly reduced the risk of worsening heart failure or cardiovascular death independently of diabetes status.
Journal ArticleDOI
Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction: Results From the DAPA-HF Trial
Mikhail Kosiborod,Mikhail Kosiborod,Pardeep S. Jhund,Kieran F. Docherty,Mirta Diez,Mark C. Petrie,Subodh Verma,Jose C. Nicolau,Béla Merkely,Masafumi Kitakaze,David L. DeMets,Silvio E. Inzucchi,Lars Køber,Felipe Martinez,Piotr Ponikowski,Marc S. Sabatine,Scott D. Solomon,Olof Bengtsson,Daniel Lindholm,Anna Niklasson,Mikaela Sjöstrand,Anna Maria Langkilde,John J.V. McMurray +22 more
TL;DR: Dapagliflozin reduced cardiovascular death and worsening heart failure across the range of baseline KCCQ, and improved symptoms, physical function, and quality of life in patients with heart failure and reduced ejection fraction.
Journal ArticleDOI
Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF).
Matthew M.Y. Lee,Matthew M.Y. Lee,Katriona Brooksbank,Kirsty Wetherall,Kenneth Mangion,Giles Roditi,Giles Roditi,Ross T. Campbell,Ross T. Campbell,Colin Berry,Colin Berry,Victor Chong,Liz Coyle,Kieran F. Docherty,John G. Dreisbach,Catherine Labinjoh,Ninian N. Lang,Vera Lennie,Alex McConnachie,Clare Murphy,Colin J. Petrie,John R. Petrie,John R. Petrie,Iain A. Speirits,Steven Sourbron,Paul Welsh,Rosemary Woodward,Aleksandra Radjenovic,Patrick B. Mark,John J.V. McMurray,Pardeep S. Jhund,Mark C. Petrie,Mark C. Petrie,Mark C. Petrie,Naveed Sattar,Naveed Sattar +35 more
TL;DR: This research presents a novel probabilistic approach that allows us to assess the importance of knowing the carrier and removal status of canine coronavirus as a source of infection for other animals.